Bhavneet Bhinder

EXaCT-2 is a whole exome sequencing platform that detects various cancer-related genomic features with high accuracy and sensitivity, outperforming standard assays in detecting sub-clonal mutations and molecular metrics.

This study identifies TMEJ as the main repair pathway for APOBEC3A-induced DSBs and shows Polθ inhibition causes synthetic lethality in cancer cells with APOBEC3A activity.

This study develops a pan-cancer PDO platform to preserve tumor heterogeneity and identify therapeutic vulnerabilities, finding that 58% of PDOs respond to Talazoparib and combination screens reveal resistance-overcoming drugs.

This study profiles early-stage lung adenocarcinoma using multiplexed imaging mass cytometry to reveal two progression pathways: inflammation-driven and fibrosis-driven, with EMT masking malignant cell expansion.

This study identifies immune suppressive barriers in preinvasive lung cancer progression using single-cell analyses, revealing key cellular and spatial changes that could inform therapeutic strategies.

This study shows that loss of GPR52 in breast cancer cells increases cell clustering, EMT features, and tumor burden in zebrafish, suggesting GPR52 as a potential therapeutic target.

This study shows that APOBEC3G drives mutagenesis and clonal evolution in bladder cancer, contributing to mutational profiles in multiple cancer types.

The paper performs an RNAi screen to identify host genes involved in Dengue virus infection, finding 1,730 genes that inhibit infection and 194 that enhance it, and identifies a common gene signature across multiple screens.

The paper identifies FBXW7 mutations as a prognostic marker in canine B-cell lymphoma using exome sequencing and clinical data.

The paper analyzes bulk RNA-seq data to identify factors influencing immune cell infiltration in human tissues, finding associations with age, sex, and genetic variants.

The paper trains a random forest classifier, ForestMHC, to predict MHC-I peptide presentation using a million human peptides, outperforming existing tools on test sets and mass spectrometry data.